TherapeuticsMD Inc

TherapeuticsMD Inc has a market capitalization of $23.6 million and a price-to-book ratio of 0.88, indicating that the company is trading at a discount to its book value. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. The current ratio of 3.02 indicates strong short-term liquidity, with current assets significantly exceeding current liabilities. The company reported a net loss of $569,000 and an operating loss of $4.39 million in the latest period, resulting in a negative return on equity of -2.12% and a negative return on assets of -1.51%. These figures are below the industry median for profitability metrics, indicating that the company is underperforming relative to its peers in terms of generating returns for shareholders and asset utilization. TherapeuticsMD Inc's revenue is concentrated in a single business segment focused on women's health products, with no disclosed geographic diversification. The company's revenue concentration in a single therapeutic area and geographic market increases its exposure to market-specific risks, such as regulatory changes or competitive pressures in the women's health sector. The company's revenue growth trajectory is uncertain, with no significant revenue growth reported in the latest period. The lack of operating cash flow growth and the presence of a net loss suggest that the company is not currently generating sufficient cash to fund operations or reinvest in growth. The absence of disclosed capital expenditures or R&D investments further limits visibility into future growth drivers. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no long-term debt and a strong current ratio, which reduces the likelihood of liquidity stress. However, the company's negative net income and operating cash flow could limit its ability to fund operations without external financing. The dilution risk is currently low, but the company's reliance on equity financing in the past suggests that dilution could become a concern if the company requires additional capital. Recent events include the company's continued focus on its core women's health portfolio, with no major product launches or strategic acquisitions disclosed in the latest filings. The company's 10-K filing highlights ongoing challenges in the competitive landscape and the need for continued investment in sales and marketing to maintain market share.